SCHEMBL30487464

SCHEMBL30487464

CCOC(=O)C[C@@H](c1cc(Cl)cc(Cl)c1)N(C)C1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 2/20 0.37
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
NR1H2 P55055 1/20 0.36
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
NOTCH1 P46531 1/20 0.34
USP30 Q70CQ3 2/20 0.34
NAMPT P43490 1/20 0.34
DPP4 P27487 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20157734 0.90 ALDH1A1 (0.44) STSALDH1A1SMN1; SMN2NPSR1TP53
SCHEMBL23747269 0.88 STS (0.36) STSDDB1CRBNALDH1A1SMN1; SMN2
SCHEMBL20141452 0.86 SMN1; SMN2 (0.36) ALDH1A1SMN1; SMN2NPSR1LMNADPP4
SCHEMBL20158218 0.80 STS (0.42) STSALDH1A1SMN1; SMN2NPSR1NR1H2
SCHEMBL20157752 0.79 STS (0.44) STSALDH1A1SMN1; SMN2NPSR1TP53
SCHEMBL30487540 0.77 STS (0.35) STSALDH1A1SMN1; SMN2NPSR1TP53
SCHEMBL21314409 0.74 SMN1; SMN2 (0.33) ALDH1A1SMN1; SMN2NPSR1LMNAGAA
SCHEMBL21317536 0.74 STS (0.50) STSALDH1A1SMN1; SMN2NPSR1TP53
SCHEMBL20157732 0.72 STS (0.39) STSALDH1A1SMN1; SMN2NPSR1TP53
SCHEMBL21564441 0.68 NR1H2 (0.43) SMN1; SMN2NR1H2NAMPTDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors ITGB1, ITGB2, ITGA1 STS 1072/4885DDB1 4119/4885CRBN 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.